Fatty liver disease (MASLD/MASH) trials in Greece
5 of 7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Where
- Thessaloníki
- Age
- 18 years to 80 years
- People
- 2,150 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06528314 - Phase 3Taking peopleA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Where
- Athens, Thessaloniki
- Age
- 18 years and over
- People
- 205 worldwide
- Run by
- Akero Therapeutics Inc.
See details and how to join2024-512895-36-00 - Phase 3Not yet taking people in GreeceA pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
- Where
- Athens, Heraklion, Thessaloniki
- Age
- 18 years and over
- People
- 382 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 - Phase 3Not yet taking people in GreeceA study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
- Where
- Athens, Heraklion, Thessaloniki
- Age
- 18 years and over
- People
- 69 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 - Phase 3Taking peopleA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- Where
- Athens, Heraklion, Thessaloniki
- Age
- 18 years to 75 years
- People
- 1,250 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00